RAB11FIP3

Across TCGA pan-cancer cohorts, RAB11FIP3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RAB11FIP3 data layer compared with 26 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RAB11FIP3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RAB11FIP3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, STAD, and UCEC are the cancer types where RAB11FIP3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.147	0.648	.015	21	view →
STAD	OS	Median	All	0.199	0.730	.002	12	view →
UCEC	DFS	Median	All	1.000	0.636	.041	8	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
LUAD	DFS	Median	All	0.049	0.814	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RAB11FIP3–HNSC (OS)

Open the HNSC breakdown →